Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae512 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Bhavana Konda und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Moffitt Cancer Center, Mayo Clinic, Rochester, NCI NIH HHS.
Abstract (Originalsprache)
Background
This investigator-initiated phase II trial aimed to evaluate the efficacy of cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) in previously treated patients with radioactive iodine-refractory differentiated thyroid cancer.
Methods
Eligible patients with radioactive iodine-refractory differentiated thyroid cancer who progressed on 1 prior line of vascular endothelial growth factor receptor-targeted therapy received a 2-week run-in of cabozantinib monotherapy followed by CaboNivoIpi for 4 cycles (cycle length = 6 weeks), followed by cabozantinib plus nivolumab (cycle length = 4 weeks) until disease progression. The primary endpoint was objective response rate (ORR) within the first 6 months of treatment. A Simon optimal 2-stage design allowed for an interim analysis after accrual of 10 evaluable patients. At least 5 responses were needed to proceed to stage 2.
Results
Among 11 patients enrolled, the median age was 69 years. Prior vascular endothelial growth factor receptor-targeted therapies included lenvatinib, pazopanib, and sorafenib plus everolimus. Median follow-up was 13.4 months. Among 10 evaluable patients, ORR within the first 6 months of treatment was 10% (1 partial response). Median progression-free survival was 9 months (95% CI, 3.0–not reached) and median overall survival was 19.2 months (95% CI, 4.6–not reached). Grade 3/4 treatment-related adverse events (AEs) were noted in 55% (6/11) and grade 5 AEs in 18% (2/11) of patients. The most common treatment-related AE was hypertension. The study did not reach its prespecified efficacy threshold.
Conclusion
CaboNivoIpi had low ORRs and a high rate of grade ≥3 treatment-related AEs. Clinical Trial Registration NCT03914300
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
- Department of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
- Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
- Departments of Endocrinology & Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN 55905, USA.
ORCID-Profile: Bhavana Konda, Howard Streicher
Förderung
- Moffitt Cancer Center
- Mayo Clinic, Rochester
- NCI NIH HHS
- University of Southern California
- City of Hope Cancer Center
- Memorial Sloan Kettering
- The Ohio State University Comprehensive Cancer Center
- National Cancer Institute
Zitieren
APA
Konda, B., Sherman, E. J., Massarelli, E., Nieva, J., Muzaffar, J., Morris, J. C., Ryder, M., Ho, A. L., Agulnik, M., Wei, L., Handley, D., Moses, C., Jacob, R., Wright, J., Streicher, H., Carson, W., & Shah, M. H. (2025). Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae512
Vancouver
Konda B, Sherman EJ, Massarelli E, Nieva J, Muzaffar J, Morris JC, et al. Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae512
BibTeX
@article{Konda2025,
author = {Konda, Bhavana and Sherman, Eric J and Massarelli, Erminia and Nieva, Jorge and Muzaffar, Jameel and Morris, John C and Ryder, Mabel and Ho, Alan L and Agulnik, Mark and Wei, Lai and Handley, Demond and Moses, Catherine and Jacob, Rajani and Wright, John and Streicher, Howard and Carson, William and Shah, Manisha H},
title = {Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae512}
}
EUVIMED